85%Confidence
0Views
FDASource
2026-05-27Date
Summary
Lead and lithium contamination in Acella's naproxen suspension raises serious health hazards and liability risks. This may result in product withdrawal, lawsuits, and damage to Acella's reputation.
Actionable: Divest from Acella Pharmaceuticals; monitor for class-action lawsuits and FDA enforcement.
AI Confidence: 85%
Data Points
firmAcella Pharmaceuticals, LLC
classificationClass II
statusOngoing
distributionNationwide
productNAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now